{"schema_version":"secwatch.filing_event.v1","accession":"0000927066-22-000131","form_type":"8-K","ticker":"DVA","cik":"0000927066","company_name":"DAVITA INC.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.677264+00:00","generated_at":"2026-06-24T06:45:27.864296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DaVita Q2 2022 EPS $2.30, revenue $2.93B; six-month net income down 27% YoY","bullets":["Q2 2022 revenue $2.927B, operating income $433M, diluted EPS $2.30 (vs Q1 2022 EPS $1.61).","Six-month net income $387M ($3.90/sh) vs $531M ($4.72/sh) in prior year, down 27%.","U.S. normalized non-acquired treatment growth was -1.9% YoY; per-day treatments up 0.9% QoQ.","Patient care costs per treatment improved to $247.14 (Q2) from $252.61 (Q1); G&A rose to $241M.","Repurchased 3.9M shares at $95.56 in Q2; additional 0.9M at $82.94 in July."],"urls":{"canonical":"https://secwatch.observer/filing/0000927066-22-000131","json":"https://secwatch.observer/filing/0000927066-22-000131.json","markdown":"https://secwatch.observer/filing/0000927066-22-000131.md","text":"https://secwatch.observer/filing/0000927066-22-000131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/927066/000092706622000131/0000927066-22-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/927066/000092706622000131/dva-20220801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:45:27.864296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}